Joseph Leveque
Direktor/Vorstandsmitglied bei ImmunOs Therapeutics AG
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Robert Bradway | M | 61 | 18 Jahre | |
Phil Holzer | M | 48 | 11 Jahre | |
John Reed | M | 65 | 4 Jahre | |
Marcos Milla | M | 61 |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | 5 Jahre |
Esteban Santos | M | 56 | 17 Jahre | |
Sean R. Smith | M | - |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | - |
Marie Debans | F | - | 4 Jahre | |
Christoph Renner | M | - |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | - |
Osiris Marroquin Belaunzaran | M | - |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | - |
Louis Schmukler | M | - | 13 Jahre | |
Philip Johnson | M | 59 | 6 Jahre | |
Darren J. Carroll | M | - | 6 Jahre | |
Daniel Vasella | M | 70 |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | 2 Jahre |
Ravi Kiron | M | 64 |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | 7 Jahre |
Michael Baran | M | - |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | - |
Gordon Brooks | M | - | 6 Jahre | |
Jeffrey D. Abbey | M | 61 |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | 3 Jahre |
Reinhard Ambros | M | 67 |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | - |
Shelley Chu | M | 54 |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | - |
Chris Round | M | - |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | 7 Jahre |
Markus Hosang | M | - |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | - |
Zack Newman | M | - | 11 Jahre | |
Andreas Jurgeit | M | - |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Peter van Vlasselaer | M | 64 | 8 Jahre | |
Jay Lichter | M | 62 | - | |
Paul Eisenberg | M | - | 14 Jahre | |
John E. Osborn | M | 66 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | 13 Jahre |
Pratik Shah | M | 54 | 4 Jahre | |
Laura Shawver | M | 66 | 3 Jahre | |
Floyd E. Romesberg | M | 58 | 5 Jahre | |
Thomas Lynch | M | 63 | 5 Jahre | |
John E. Celentano | M | 64 | 31 Jahre | |
Shalini Sharp | F | 49 | 3 Jahre | |
Brian Daniels | M | 65 | 14 Jahre | |
Peter Kolchinsky | M | 47 | 2 Jahre | |
Gerald J. Pappert | M | 60 |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | - |
Tighe Reardon | M | 48 | 5 Jahre | |
Daniel Faga | M | 44 | 1 Jahre | |
Peter Thompson | M | 64 | 2 Jahre | |
Sriram Ryali | M | 43 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 4 Jahre |
William Ashton | M | 73 | 16 Jahre | |
Jason Haddock | M | 54 | 14 Jahre | |
Gregory L. Tewalt | M | - | - | |
David Meek | M | 59 | 2 Jahre | |
Herbert Cross | M | 52 | 1 Jahre | |
Beth Seidenberg | M | 67 | 10 Jahre | |
Michael Grey | M | 71 | 7 Jahre | |
Anthony Hooper | M | 69 | 15 Jahre | |
Dinesh C. Paliwal | M | 67 | 8 Jahre | |
William Ringo | M | 78 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 Jahre |
Robert Williams | M | 75 | 7 Jahre | |
Timothy Martin | M | 55 | 3 Jahre | |
Nathan Hardy | M | 48 | 10 Jahre | |
Louis J. Freeh | M | 74 | 8 Jahre | |
Béatrice J. Cazala | F | 67 | 32 Jahre | |
Suzanne M. Shema | F | 66 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | - |
Helen Torley | M | 61 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 Jahre |
Leif Valdemar Johansson | M | 73 | 13 Jahre | |
Charles Sigal | M | 72 | 16 Jahre | |
Gerald Storch | M | 67 | 12 Jahre | |
Vickie Capps | F | 62 | 2 Jahre | |
Andrew Powell | M | 66 | 2 Jahre | |
Robert Berman | M | 61 | 10 Jahre | |
Linda Kozick | F | 66 | 4 Jahre | |
Winston Kung | M | 48 | 3 Jahre | |
Richard Peters | M | 61 | 3 Jahre | |
Ann Miller | M | 66 | 5 Jahre | |
Rebecca Drain | F | 61 | 3 Jahre | |
Karen Murphy Santiago | F | 53 | 10 Jahre | |
Margrit Schwarz | M | 60 | 7 Jahre | |
Ronald Peck | M | 58 | 4 Jahre | |
Eliot Charles | M | 62 | 3 Jahre | |
Kenneth Lock | M | 50 | 6 Jahre | |
David Weinreich | M | - | 7 Jahre | |
Sesha Neervannan | M | 56 | 8 Jahre | |
Christophe Quéva | M | 57 | 5 Jahre | |
Elliott Levy | M | 64 | 17 Jahre | |
David Tuck | M | 72 | 3 Jahre | |
Kelly Schick | F | 44 | - | |
Ronald Marcus | M | 65 | 22 Jahre | |
Katrin Rupalla | M | 56 | 7 Jahre | |
Carlo de Notaristefani | M | 67 | 7 Jahre | |
John F. Weidenbruch | M | 63 | 10 Jahre | |
Doug Farrar | M | 59 | 7 Jahre | |
Jeremy Levin | M | 70 | 5 Jahre | |
Lisa A. Evrén | F | - | 5 Jahre | |
Frances K. Heller | F | 57 | - | |
Andres Gutiérrez | M | 63 | 3 Jahre | |
Warren Wayne Myers | M | 62 | 10 Jahre | |
H. Christian Fibiger | M | 80 | 4 Jahre | |
Jeffrey Wiezorek | M | 52 | 8 Jahre | |
Giuseppe Giorgini | M | - | - | |
Tony Webster | M | 55 | 7 Jahre | |
Axel Hoos | M | 54 | 6 Jahre | |
Sheila Gujrathi | M | 53 | 3 Jahre | |
Annalisa Jenkins | M | 58 | 2 Jahre | |
Rachel Humphrey | M | 62 | 9 Jahre | |
Scott M. Wasserman | M | - | 14 Jahre | |
Marlene Haffner | M | 83 | 2 Jahre | |
Edward Atkinson | M | 58 | 8 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 90 | 90,00% |
Schweiz | 11 | 11,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Joseph Leveque
- Persönliches Netzwerk